ArticleEndocrine2014
Cardiovascular events in acromegaly: distinct role of Agatston and Framingham score in the 5-year prediction.
Article in Endocrine, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 1 synthesis or guideline pooled it, 22 citations in OpenAlex.
- Preclinical markers of atherosclerosis in acromegaly: a systematic review and meta-analysis.Pituitary · 2018Pooled it
- Clinical subtypes of co-morbid insomnia and obstructive sleep apnea (COMISA): results of a cluster analysis.Respiratory research · 2026Article
- Assessment of osteoprotegerin and RANKL levels and several cardiovascular risk scoring systems in acromegaly.Hormones (Athens, Greece) · 2024Article
- How to position sodium-glucose co-transporter 2 inhibitors in the management of diabetes in acromegaly patients.Endocrine · 2023Review
- Serum NT-pro-BNP Levels Predict Cardiovascular Events in Acromegaly Patients.Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association · 2022Article
- Advances in Research on the Cardiovascular Complications of Acromegaly.Frontiers in oncology · 2021Review
- Cardiometabolic Risk in Acromegaly: A Review With a Focus on Pasireotide.Frontiers in endocrinology · 2020Review
- Current perspectives on the impact of clinical disease and biochemical control on comorbidities and quality of life in acromegaly.Reviews in endocrine & metabolic disorders · 2019Review
- GSTP1 gene methylation and AHR rs2066853 variant predict resistance to first generation somatostatin analogs in patients with acromegaly.Journal of endocrinological investigation · 2019Observational
- Review
- The Endothelium in Acromegaly.Frontiers in endocrinology · 2019Review
- Serum paraoxonase level and paraoxonase polymorphism in patients with acromegaly.Redox report : communications in free radical research · 2016Article
- Low risk of coronary artery disease in patients with acromegaly.Endocrine · 2015Article
- Optimal use of pegvisomant in acromegaly: are we getting there?Endocrine · 2015Article
- Article
Corrections and comments
- Commented on by
Authors and funding
11 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Prediction of ischemic cardiovascular events (ICE) in acromegalic patients stratified accordingly with Framingham (FS) and Agatston score (AS). 32 patients with active (group A (0)) and 20 with controlled (group B (0)) acromegaly have been enrolled. During the 5-year follow-up, 19 out of 32 patients in group A (0) reached disease control. At entry, FS and AS, by an eight-slice MDCT scanner, were calculated in all patients. ICE were diagnosed by autopsy, if lethal, and by electrocardiography and/or echocardiography, if non-lethal. Overall, 9.6 % of patients died for lethal ICE. AS >400, but not high FS at entry, was associated with increased risk of lethal ICE. Lethal ICE had occurred in two patients of group A (0) and three of group B (0) (p NS), while a non-lethal ICE had occurred in two cases of the former and in other two of the latter group (p NS). Either FS or AS was correlated with the risk for ICE overall (p < 0.02), but only AS correlated with that of lethal ICE (p < 0.0003). Survival analysis demonstrated reduced life expectancy in patients with high FS (p < 0.02). In acromegalics, AS >400 is associated with increased risk of lethal ICE, while high FS is associated with reduced life expectancy, regardless of disease control.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.